This is the definitive, one-stop resource on preclinical drug evaluation for potential mitochondrial toxicity, addressing the issue upfront in the drug development process. It discusses mitochondrial impairment to organs, skeletal muscle, and nervous systems and details methodologies used to assess mitochondria function. It covers both in vitro and in vivo methods for analysis and includes the latest models. This is the authoritative reference on drug-induced mitochondrial dysfunction for safety assessment professionals in the pharmaceutical industry and for pharmacologists and toxicologists in both drug and environmental health sciences.

James A. Dykens, PhD, is an Associate Research Fellow in Pfizer's Drug Safety Research and Development Department. Currently in Sandwich, England, he previously worked in a similar role with Pfizer in La Jolla, California. Prior to his work with Pfizer, Dr. Dykens was the senior director of technology development for MIGENIX Inc., a senior scientist and the director of business development at MitoKor, Inc., and a senior principal scientist at Parke-Davis Pharmaceutical Research. Dr. Dykens has published extensively on drug-induced mitochondrial dysfunction, on the role of mitochondrial free radical production in the etiology of neurodegenerative diseases, and on the physiological ecology of marine symbioses.

Yvonne Will, PhD, works in Pfizer's Exploratory Safety Differentiation Group in Groton, Connecticut. Prior to this position, she led Pfizer's Investigative Biochemical Toxicity Group within the Drug Safety Research and Development Department in La Jolla. Before joining Pfizer, Dr. Will worked on mitochondrial proteomics and physiology at MitoKor, Inc. Dr. Will has authored a host of articles and book chapters. She is a member of the Society of Toxicology and a frequent speaker for groups like ACT and World Pharmaceutical Congress.